Your Patients Need Mydayis — Here's How You Can Help

If you prescribe Mydayis for ADHD, you've almost certainly heard from frustrated patients who can't find their medication. The ongoing amphetamine shortage has turned what should be a routine prescription fill into an exhausting search for many of your patients.

As a provider, you're in a unique position to help. This guide offers practical, actionable steps you can take to support your patients in finding Mydayis — and what to do when the medication simply isn't available.

Current Mydayis Availability

As of early 2026, Mydayis remains intermittently available across the United States. The broader amphetamine shortage that began in October 2022 has improved following DEA production quota increases in fall 2025, but supply remains inconsistent — particularly for extended-release formulations and niche products like Mydayis.

Key availability facts:

• ASHP continues to list amphetamine ER products in shortage with multiple manufacturers on back order
• Brand Mydayis is available through Takeda but pharmacy stocking is inconsistent
• Generic Mydayis (mixed amphetamine salts ER) has FDA approval but pharmacy availability varies by region
• Independent pharmacies generally have more success sourcing Mydayis than large chains
• Mail-order pharmacies may have access to different supply channels

For the latest on the shortage, see our provider briefing on the Mydayis shortage.

Why Patients Can't Find Mydayis

Understanding the barriers helps you address them more effectively:

Supply-side constraints

• DEA quotas limit annual amphetamine production, even after the 2025 increases
• Manufacturing complexity — Mydayis's triple-bead formulation requires specialized production
• Limited manufacturers — fewer companies make Mydayis compared to generic Adderall XR

Distribution challenges

• Wholesaler allocation: Pharmacies receive controlled substance allocations based on historical ordering patterns. Pharmacies that haven't dispensed Mydayis before may have difficulty ordering it.
• Chain pharmacy limitations: Large chains often have centralized ordering that limits individual store flexibility
• Geographic disparities: Rural areas and some regions have significantly worse availability

Patient-level barriers

• Schedule II restrictions: Prescriptions can't be transferred between pharmacies. Patients need a new prescription for each pharmacy.
• Cost: Brand Mydayis costs $345-$466 without insurance. Even with coupons, the generic runs $90-$150.
• Information gap: Many patients don't know how to search for pharmacies with stock or that tools like Medfinder exist

What Providers Can Do: 5 Actionable Steps

Step 1: Use Medfinder to Check Availability Before Prescribing

Before sending a prescription to a pharmacy, check Medfinder for Providers to see which pharmacies in your patient's area currently have Mydayis in stock. This simple step can prevent your patient from showing up at a pharmacy that doesn't have their medication.

Consider making this a standard workflow step for all controlled substance prescriptions during the shortage.

Step 2: Use EPCS to Redirect Prescriptions Quickly

Electronic Prescribing for Controlled Substances (EPCS) allows you to send Mydayis prescriptions to any pharmacy electronically. When a patient reports their pharmacy is out of stock, you can quickly send a new prescription to a pharmacy that has it — sometimes during the same office visit or phone call.

This is much faster than writing paper prescriptions and having patients drive to multiple pharmacies.

Step 3: Consider Prescribing Multiple 30-Day Supplies

In many states, you can write multiple Schedule II prescriptions with sequential fill dates (e.g., one for immediate fill, one with a "do not fill until" date 30 days out). Check your state's specific regulations.

This approach gives patients the security of knowing they have their next prescription ready to go, and they can focus on finding a pharmacy with stock ahead of their next fill date.

Step 4: Discuss Alternatives Proactively

Don't wait until your patient can't find Mydayis to discuss backup plans. During routine ADHD follow-ups, have a brief conversation about what you'd recommend if Mydayis becomes unavailable. The main alternatives are:

• Vyvanse (Lisdexamfetamine): Up to 14 hours of coverage, generic now available. Closest in duration to Mydayis. Cost: $30-$80 for generic with coupon.
• Adderall XR: Same active ingredients but ~12 hours. May need afternoon IR booster. Generic widely available at $30-$80 with coupon.
• Concerta (Methylphenidate ER): Different class, ~12 hours. Not affected by amphetamine shortage. Generic: $25-$60 with coupon.
• Jornay PM: Evening-dosed methylphenidate. Brand only. Good for patients with morning symptom burden.

For detailed alternative comparisons, share our patient guide to Mydayis alternatives.

Step 5: Connect Patients with Cost-Saving Resources

Cost is often a secondary barrier on top of availability. Equip your patients with these resources:

• GoodRx, SingleCare, RxSaver: Coupon cards that reduce generic Mydayis cost to $90-$150
• Takeda Help at Hand: Patient assistance program for uninsured/underinsured patients (helpathandpap.com)
• NeedyMeds.org: Comprehensive directory of patient assistance programs

Direct patients to our guide on saving money on Mydayis for detailed information.

Alternative Medications at a Glance

Here's a quick reference for your prescribing decisions:

• Vyvanse (Lisdexamfetamine): 10-70 mg capsules/chewable. Duration: ~14 hours. Prodrug mechanism. Generic available.
• Adderall XR (Mixed Amphetamine Salts ER): 5-30 mg capsules. Duration: ~12 hours. Dual-bead system. Generic widely available.
• Concerta (Methylphenidate ER): 18-54 mg tablets. Duration: ~12 hours. OROS delivery system. Generic available. Different stimulant class.
• Jornay PM (Methylphenidate): 20-100 mg capsules. Evening dosing. Brand only. Different stimulant class.
• Strattera (Atomoxetine): Non-stimulant SNRI. 24-hour coverage. Generic available. Lower efficacy but no shortage concerns.

Remember: Mydayis cannot be substituted for other amphetamine products on a milligram-per-milligram basis due to its unique triple-bead formulation and different amphetamine base compositions.

Workflow Tips for Managing the Shortage

Integrate these practices into your clinical workflow:

At every ADHD visit:

• Ask about medication access — "Have you had any trouble filling your Mydayis prescription?"
• Review insurance coverage and prior authorization status
• Document any shortage-related issues in the chart (supports future prior auth appeals)

For front office staff:

• Train staff to check Medfinder when patients call about shortage issues
• Create a template response for patients who call about the shortage, including links to Medfinder and cost-saving resources
• Keep a list of local independent pharmacies that have historically been able to source Mydayis

For follow-up:

• Schedule follow-ups every 1-2 months during the shortage (rather than the typical 3-month interval) to monitor for treatment disruptions
• Consider telehealth follow-ups for prescription management to reduce patient burden
• Document shortage-related medication changes to facilitate returning to Mydayis when supply improves

Final Thoughts

The Mydayis shortage requires providers to be more proactive and flexible than usual. By checking availability before prescribing, using EPCS for quick redirects, discussing alternatives early, and connecting patients with cost-saving tools, you can significantly reduce the impact of the shortage on your patients' treatment.

The situation is improving, but it requires ongoing attention. Stay informed through ASHP and FDA shortage databases, and continue to advocate for your patients' access to the medications they need.

For a comprehensive overview of the shortage and its clinical implications, see our provider briefing on the Mydayis shortage in 2026.